Zumutor Biologics is a cutting-edge brand founded in 2015, with headquarters in Woburn, MA, USA, and a state-of-the-art laboratory in Bangalore, India. With a strong focus on immuno-oncology and antibody engineering technologies, Zumutor has garnered considerable success in the field. They have raised a total of $12 million in capital from prestigious investors, including Accel Partners, IDG Ventures, Aarin Capital, and KITVEN, and an additional $6 million from Accel and BIF to advance their immuno-onco lead molecules into pre-clinical trials.

One of Zumutor's key strengths is their highly skilled cross-functional team that works alongside external scientific advisors, offering diverse and profound knowledge in immuno-oncology. They have achieved significant milestones, including global licensing of a biologic product for breast cancer treatment and multiple collaborations with technological partners in Europe and the USA. Since their inception, Zumutor has made remarkable progress, developing advanced technology platforms such as Glyco-Engineering and Naïve & Synthetic Display Libraries.

They have also worked on the development of important substances like trastuzumab biosimilar and Exendin-4. With a strong dedication to innovation and research, Zumutor continues to make strides in the field of biologics, promising a brighter future for patients worldwide